Autolus Therapeutics (AUTL) vs Eikon Therapeutics (EIKN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Eikon Therapeutics is the larger company by market cap ($256.8 million vs $241.7 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AUTL | EIKN |
|---|---|---|
| Share price | $0.9073 | $4.74 |
| Market cap | $241.65M | $256.84M |
| 1-day change | -7.38% | -0.42% |
| YTD return | -54.41% | — |
| 1-year return | -26.24% | — |
| 5-year return | -85.51% | — |
| EPS (TTM) | $-0.96 | $-7.86 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $75.39M | — |
| Revenue growth (YoY) | +644.94% | — |
| Net income (latest FY) | $-287.53M | — |
| Gross margin | -27.83% | — |
| Operating margin | -358.87% | — |
| Net margin | -381.40% | — |
| 52-week high | $2.58 | $17.40 |
| 52-week low | $0.896 | $4.72 |
| Distance from 52-week high | -64.83% | -72.76% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +821.42% | +406.33% |
| Average volume | 2.07M | 560.40K |
| Shares outstanding | 266.34M | 54.19M |
| Employees | 752 | 384 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Autolus Therapeutics
AUTL stock →Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in the United Kingdom and internationally. The company offers AUCATZYL, a gene therapy product consisting of autologous T cells that are transduced with a lentiviral vector to express a novel anti-CD19 chimeric antigen receptor.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 752 employees
About Eikon Therapeutics
EIKN stock →Eikon Therapeutics, Inc., operates as a clinical biopharmaceutical company in the United States. It develops medicines to address serious unmet medical needs.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 384 employees
AUTL vs EIKN FAQ
Which is bigger, Autolus Therapeutics or Eikon Therapeutics?
Eikon Therapeutics (EIKN) is larger, with a market capitalization of $256.84M compared with $241.65M for Autolus Therapeutics (AUTL).
Are Autolus Therapeutics and Eikon Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.